scholarly journals Pulmonary Large Cell Neuroendocrine Carcinoma: A Rare Type of Non-Small Cell Lung Cancer

Cureus ◽  
2021 ◽  
Author(s):  
Thomas G Ng ◽  
Hyo-bin Um ◽  
Mark Forsberg ◽  
Usha Trivedi ◽  
Jason George
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Small Cell Lung ◽  
Rare Type

Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600–Mutated Tumor Responding to Targeted Therapy

2018 ◽  
pp. 1-12
Author(s):  
Young Kwang Chae ◽  
Keerthi B. Tamragouri ◽  
Jon Chung ◽  
Xiaoqi Lin ◽  
Vincent Miller ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Small Cell Lung ◽  
Durable Response ◽  
Biomarker Response

Purpose In advanced stages, large-cell neuroendocrine carcinoma of the lung (L-LCNEC) mimics small-cell lung cancer despite its traditional classification as a non–small-cell lung cancer. Here we present a focused analysis of BRAF mutations in this population. Patients and Methods Comprehensive genomic profiling of tumor tissues was performed from a cohort of 300 patients with biopsy-proven L-LCNEC. Specimens were either from a primary lung lesion or metastatic site. Results In 13 patients, 14 unique BRAF alterations (amplifications, mutations) were identified. The importance of biomarker-driven therapy is subsequently highlighted with our case of a 69-year-old man diagnosed with metastatic L-LCNEC who did not respond to cisplatin plus etoposide. A significant durable response was then demonstrated with therapy targeted toward a BRAF non-V600E activating mutation (G469R) associated with biomarker response identified through circulating cell-free tumor DNA analysis. A change in clonal allele frequency from nearly 40% to nondetectable was observed. Conclusion Although uncommon, L-LCNEC does seem to contain activating and therefore actionable alterations. We thus highlight the value of pursuing next-generation sequencing for patients with this disease.

scholarly journals SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study

Lung Cancer ◽  
2020 ◽  
Vol 145 ◽  
pp. 126-131
Author(s):  
Daniel Morgensztern ◽  
Melissa Johnson ◽  
Charles M. Rudin ◽  
Michael Rossi ◽  
Mirella Lazarov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Small Cell Lung ◽  
Phase 1 Study

Molecular landscape of BRAF mutations in large cell neuroendocrine carcinoma of lung: An analysis of BRAF mutations and a case report of a BRAF non-V600E mutated tumor responding to targeted therapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11621-11621 ◽  
Author(s):  
Keerthi Tamragouri ◽  
Young Kwang Chae ◽  
Jon Chung ◽  
Vincent A. Miller ◽  
Siraj Mahamed Ali ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Small Cell Lung ◽  
Braf Mutations ◽  
Durable Response

11621 Background: In advanced stages, large cell neuroendocrine carcinoma of the lung (L-LCNEC) mimics small cell lung cancer (SCLC) despite its traditional classification as a non-small cell lung cancer (NSCLC). Here we present a focused analysis of BRAF mutations in this population. Methods: Comprehensive genomic profiling of tumor tissues was performed from a cohort of 300 patients with biopsy proven L-LCNEC. Specimens were either from a primary lung lesion or metastatic site. Results: 14 unique BRAF alterations (amplifications, mutations) were identified in 13 patients. The importance of biomarker driven therapy is subsequently highlighted with our case of a 69 year-old male diagnosed with metastatic L-LCNEC that did not respond to cisplatin/etoposide. He then demonstrated a significant durable response with therapy targeted toward a BRAF non-V600E mutation (G469R) associated with biomarker response identified through circulating cell free tumor DNA analysis. A change in clonal allele frequency from nearly 50% to non-detectable was observed. Conclusions: Though uncommon, L-LCNEC does appear to contain activating and therefore actionable alterations. We thus highlight the value of pursuing NGS for these patients. [Table: see text]

scholarly journals Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer

2005 ◽  
Vol 130 (1) ◽  
pp. 166-172 ◽  
Author(s):  
Richard J. Battafarano ◽  
Felix G. Fernandez ◽  
John Ritter ◽  
Bryan F. Meyers ◽  
Tracey J. Guthrie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Small Cell Lung ◽  
Aggressive Form
Sign in / Sign up

Export Citation Format

Share Document